A New Tool for Assessing Asthma Control: What Clinicians Should Know About the AIRQ

Here’s an excerpt from the analysis published in the Annals of Allergy, Asthma & Immunology:

From our partner

Expert Videos: Learn how early UACR testing can help reveal hidden CKD and related cardiovascular risk, even when eGFR appears normal.

“National and international asthma guidelines and reports do not include control tools that combine impairment assessment with exacerbation history in one instrument. To analyze the performance of the composite Asthma Impairment and Risk Questionnaire (AIRQ) in assessing both domains of control and predicting exacerbation risk compared with the Global Initiative for Asthma (GINA) 4-question symptom control tool (GINA SCT), Asthma Control Test (ACT), and physician expert opinion (EO) informed by GINA SCT responses and appraisal of GINA-identified risk factors for poor asthma outcomes.”

From our partner

Vitiligo doesn’t have to keep you down - Find out how the FPAD clinical trial may help!

Why Is This Important?

AIRQ performs better in assessing both domains of current control and predicting exacerbation risk than do control tools and EO informed by GINA SCT and risk factors for poor asthma outcomes.

Are you a healthcare professional? Register with us today!